Who Paid My Doc
Scott Glickman
Neurological Surgery Las Vegas, NV Doctor of Osteopathy
NPI 1679693428 CMS profile 211701
6850 N Durango Dr Ste 301, Las Vegas, NV 89149
General payments
$274,151
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Scott Glickman of Las Vegas, NV is reported in the CMS Open Payments database as having received $274,151 across 626 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 95th percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $30,707 | 19 | |
| 2024 | General | $38,506 | 36 | |
| 2023 | General | $37,883 | 55 | |
| 2022 | General | $77,180 | 134 | |
| 2021 | General | $55,687 | 129 | |
| 2020 | General | $24,145 | 88 | |
| 2019 | General | $10,042 | 165 |
Beside peers
- Scott Glickman
- Neurological Surgery median
- Middle half of Neurological Surgery
- National median
In program year 2025, general payments to Scott Glickman were reported at $30,707. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.
Show as a table
| Year | Scott Glickman | Neurological Surgery median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $10,042 | $582 | $138–$3,006 | $163 |
| 2020 | $24,145 | $294 | $76–$2,174 | $114 |
| 2021 | $55,687 | $387 | $105–$2,432 | $132 |
| 2022 | $77,180 | $542 | $139–$2,989 | $149 |
| 2023 | $37,883 | $534 | $145–$2,697 | $160 |
| 2024 | $38,506 | $574 | $155–$3,046 | $164 |
| 2025 | $30,707 | $596 | $159–$3,102 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 1 drugPart D claims
22
Drug cost
$70
Branded share of claims
0%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Meloxicam | Generic | 22 | $70 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 237 Part D prescribers listed as Neurological Surgery; they describe a distribution and say nothing about conduct.
Records
626 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Neurological Surgery in Nevada
Related records
Neurological Surgery in Nevada
Practitioners in the same specialty and state, ranked by reported value.
All Neurological Surgery
Everyone recorded under this specialty, nationwide.
Doctors in Nevada
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.